StemCell Therapy

Wilmington, Delaware, United States, July 04, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc.: The value of the global orthobiologics market was clocked at US$ 5.01 Bn in 2021. The orthobiologics marketoutlook predicts the market to rise at a CAGR of 4.7% during the forecast period, from 2022 to 2031. The global orthobiologics market is expected to attain a value surpassing US$ 7.4 Bn by 2031. Until afew years ago, orthobiologics have been a common practice in sports medicine andorthopedic surgeries. Demand analysis of orthobiologics estimates that developments in regenerative medicine, an increasing number of sports andsports-relatedinjuries, rising demand for less invasive procedures, andconstant infusion of innovative products and treatmentsare all expected to propel the global orthobiologics market.

Musculoskeletal tissue engineering and regenerative medicineresearch, however, have slowed down as a result of the COVID-19 outbreak. However,strong development potential in developing nations and a rise in demand for cutting-edge therapies are expected to create considerable prospects for companies in the growth of the orthobiologics market.

The global orthobiologics market is being driven by the increase in orthobiologics product and usage oforthopedic device. In addition to that, there is increasingincorporation of biochemistry andbiology in the treatment of soft tissue andbone injuries. Orthobiologic drugs help natural healing mechanism of the bodyto workmore quickly. They can hasten the healing of injured ligaments, tendons, andmuscles. It alsoassistsin repairing osteoarthritis damage. The materials used to develop orthobiologics are those that are normally present in the human body.

Request Brochure of Orthobiologics Market Research Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1747

Key Findings of Market Report

Request for Analysis of COVID-19 Impact on Orthobiologics Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1747

Global Orthobiologics Market: Growth Drivers

Get Exclusive PDF Sample Copy of Orthobiologics Market Report https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1747

Global Orthobiologics Market: Key Players

Some of the key market players are

Make an Enquiry Before Buying https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1747

Global Orthobiologics Market: Segmentation

Product Type

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Industry Research Reports by Transparency Market Research:

Stem Cells Market: The global stem cells market is expected to reach the value of US$ 25.68 Bn by the end of 2028.It is estimated to expand at a CAGR of 10.4% from 2021 to 2028.

Placental Stem Cell Therapy Market: The placental stem cell therapy market stood at US$ 0.5 Bn in 2019 and is expected to cross a revenue of US$ 4.4 Bn by the end of 2030.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: The global platelet rich plasma & stem cell alopecia treatment market is expected to reach a value of approximately US$ 450.5 Mn by the end of 2026, expanding at a high single digit CAGR during the forecast period.

Soft Tissue Allografts Market: The global soft tissue allografts market was valued at US$ 3.55 Bn in 2018, and is projected to reach ~ US$ 6.2 Bn by 2027, expanding at a CAGR of ~ 6.5% from 2019 to 2027.

Bone Growth Stimulators Market: The global bone growth stimulators market is anticipated to reach more than US$ 2 Bn by the end of 2031. The global market is projected to grow at a CAGR of 5.8% from 2022 to 2031.

Small Bone and Joint Orthopedic Devices Market: The global small bone and joint orthopedic devices market was valued at US$ 5.5 Bn in 2018 and is anticipated to expand at a CAGR of 6.3% from 2019 to 2027.

Metastatic Bone Disease Market: The global metastatic bone disease market was valued at US$ 12,450.0 Mn in 2017 and is anticipated to reach US$ 24,886.8 Mn by 2026, expanding at a CAGR of 8.1% from 2018 to 2026.

Bone Grafts and Substitutes Market: The global bone grafts and substitutes market is expected to cross the value of US$ 4.4 Bn by the end of 2028. It is estimated to expand at a CAGR of 4.9% from 2021 to 2028.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website:https://www.transparencymarketresearch.comBlog:https://tmrblog.comEmail:sales@transparencymarketresearch.com

Read the rest here:
Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that it will host a key opinion leader (KOL) webinar on its proprietary Human Acellular Vessels (HAV) in the treatment of vascular trauma on Thursday, July 14, 2022 at 11:30 a.m. Eastern Time.

The webinar will feature presentations from KOLs Ernest E. Moore, MD (Denver Health) and Gregory A. Magee, MD, (Keck Medicine, University of Southern California), who will discuss the current treatment landscape and unmet medical need in the vascular trauma field as well as case studies of trauma patients treated with the HAV.

Humacytes HAV are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is designed to eliminate the need for harvesting a vessel from a patient or using a synthetic graft, and clinical evidence to date suggests that it is non-immunogenic and infection-resistant and can become durable living tissue.

A question and answer session will follow the formal presentations. To register for the event, please click here.

Ernest E. Gene Moore, MD, was the Chief of Trauma at the Denver General Hospital for 36 years, Chief of Surgery for 28 years, and the first Bruce M. Rockwell Distinguished Chair in Trauma Surgery. He continues to serve as Vice Chairman for Research and is a Distinguished Professor of Surgery at the University of Colorado Denver (UCD) and was the Editor of the Journal of Trauma 2011-2021.

Under Dr. Moores leadership, the Rocky Mountain Regional Trauma Center at Denver General became internationally recognized for innovative care of the injured patient, and its trauma research laboratory has been funded by the NIH for 35 consecutive years. In July 2018, the center was renamed the Ernest E Moore Shock Trauma Center at Denver Health.

Dr. Moore has served as president of ten academic societies, including the Society of University Surgeons, American Association for the Surgery of Trauma, International Association for the Trauma and Surgical Intensive Care, and the World Society of Emergency Surgery; and as Vice President for the American Surgical Association.

His awards include the Robert Danis Prize from the Society of International Surgeons, Orazio Campione Prize from the World Society of Emergency Surgery, Philip Hench Award from the University of Pittsburgh, Florence Sabin Award from the University of Colorado, Lifetime Achievement Award from the Society of University Surgeons, Lifetime Achievement Award for Resuscitation Science from the American Heart Association, Distinguished Investigator Award from the American College of Critical Medicine, Distinguished Investigator Award from the Shock Society, Lifetime Service Award from the International Association for Trauma and Surgical Intensive Care, and the Medallion for Scientific Achievement from the American Surgical Association. He has honorary fellowships in the Royal College of Surgeons of Edinburgh, the Royal College of Surgeons in Ireland, the Royal College of Surgeons of Thailand, and the American College of Emergency Physicians; and is an honorary member of the Brazilian Trauma Society, Colombian Trauma Society, Eastern Association for the Surgery of Trauma, European Society for Trauma and Emergency Surgery, North Pacific Surgical Association, and Trauma Association of Canada. Dr. Moore is coeditor of the textbook Trauma, in its 9th edition, Surgical Secrets in its 7th edition, and Trauma Induced Coagulopathy, in its 2nd edition; he has >2000 publications and has lectured extensively throughout the world.

Gregory A. Magee, MD received his BA in Molecular Biophysics & Biochemistry from Yale University and his MSc in Applied Statistics from the University of Oxford. He earned his medical degree from Yale School of Medicine in 2006.

Dr. Magee underwent his general surgery residency at Stanford. During his two research years, Dr. Magee completed the Stanford Biodesign Surgical Innovation Fellowship, developing devices that formed the basis for two venture-funded start-up companies, both of which are currently conducting clinical trials. He continues to pursue his goal of improving medical care through technological innovation.

Dr. Magee completed a surgical critical care and trauma surgery fellowship at USC from 20132015 and a vascular surgery fellowship at the University of Colorado Denver in 2017, where he developed a broad experience in complex endovascular repair of the entire aorta using tailor-made fenestrated grafts. He is board certified in General Surgery, Surgical Critical Care, and Vascular Surgery.

About HAVHuman Acellular Vessels (HAV) are investigational engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue. The HAV is currently being evaluated in two Phase 3 trials in arteriovenous access and a Phase 2/3 trial for vascular trauma, and has been used in more than 460 patient implantations. Humacytes 6mm HAV for AV access for performing hemodialysis was the first product to receive Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA), and has also received FDA Fast Track designation. The HAV has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.

About HumacyteHumacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and complex tissue and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacytes initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacytes 6mm HAV for arteriovenous (AV) access for performing hemodialysis was the first product candidate to receive the FDAs Regenerative Medicine Advanced Therapy (RMAT) designation, and has also received FDA Fast Track designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit http://www.Humacyte.com.

Humacyte Investor Contact:Joyce AllaireLifeSci Advisors LLC+1-617-435-6602[emailprotected][emailprotected]

Humacyte Media Contact:Heather Anderson6 Degrees919-827-5539[emailprotected][emailprotected]

View post:
Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels in the Treatment of Vascular Trauma - StreetInsider.com

The3D cell culture marketrevenues surpassed US$ 778 million in 2018,as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

Request Sample Copy of Report:https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years, says FMI.

Leading Manufacturers in the 3D Cell Culture Market:

Competitive Landscape of the Global 3D Cell Culture Market

The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.

The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.

Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.

Download PDF Brochure @https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Key SegmentBased on product type

Based on application

Based on end user

Explore Other Reports Links From Healthcare Market:

https://drujrake.mn.co/posts/24898121

https://tennispassion.mn.co/posts/24898141

https://skin-care-junkies.mn.co/posts/24898157

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

See the article here:
3D Cell Culture Market to attain a valuation of US$ 2.67 Billion by 2031 - PharmiWeb.com

EVEON, designer and manufacturer of medical devices for the preparation and delivery of drugs, announces the launch of a European consortium project INDENEO, for the Rare Disease Research (RDR) Challenge Call, to develop a delivery system from the nose to the brain for the treatment of rare central nervous system (CNS) diseases like encephalitis in neonates.

The Rare Disease Research Challenge Call, launched by the European Joint Programme for Rare Diseases and co-funded by the biopharmaceutical company Chiesi Group, aims to develop a dropper system from nose to brain for biological drugs and advanced therapies in neonates. For certain rare diseases involving the CNS, for example, neonatal encephalitis, intranasal delivery allows to target the central nervous system, thanks to the transfer from the nose to the brain of the molecules. Minimally invasive and restrictive, this is recognized as one of the most useful and reliable routes for brain drug absorption leading to quick drug action, with greater efficacy and reduced risk of infection.

INDENEO (INtraNasal Device for NEOnates) project brings together an international consortium of 4 partners. EVEON, project leader, brings its expertise in the development of delivery devices and its ability to deliver microdoses; Chiesi contributes with its expertise in pharmaceutical development and neonatology; Les Cliniques universitaires Saint Luc (Belgium) brings its top level clinical expertise and Infectious Disease Models and Innovative Therapies (IDMIT) department at the CEA (Fontenay aux Roses site - France) its expertise in carrying out pre-clinical trials.

INDENEO will last 18 months with two main milestones: the design and development of a functional prototype, then the pre-clinical validation.

At EVEON, we are honored and excited to lead the INDENEO project and work together with Cliniques Saint Luc, CEA and Chiesi Laboratories for the development of a new device. Nose To Brain delivery will open up new ways to address major unmet medical needs for neonates neurological rare conditions. We are proud to work on this innovative project that is at the heart of our goals : developing automatic and controlled devices for allowing safe and efficient delivery of biological drugs. said Claire Authesserre, Technical Pre-Sales Manager and Gladys Corrons-Bouis, Business Development Director, EVEON.

Story continues

As Chiesi Global Rare Diseases we are excited to contribute to such an important project to enhance the possibilities of successfully treating rare central nervous system (CNS) diseases in neonates. Our Company has a long history in the field of neonatology, which is combined here with our commitment to rare diseases - commented Diego Ardig, Head of R&D Rare Disease Unit at Chiesi Group -. We truly believe in the power of collaboration in the advancement of scientific research, because by combining expertise and resources you can answer bigger and more complex scientific questions and generate greater value. We are also driven by our desire to bring new or improved treatments and services to people suffering from rare diseases and debilitating chronic conditions, always focusing on the often-unseen needs, where we can make the biggest difference. We are committed to giving our patients and their loved ones the support they need to lead more active and fulfilling lives.

Stem cells hold tremendous promise for regenerative medicine. Preclinical research suggest that stem cells may represent the next breakthrough in the repair of currently devastating brain injury in neonates, including stroke and hypoxic-ischemic lesions. Recent safety studies in human neonates have suggested that the nasal route may be the most efficient way to deliver stem cells in the neonatal brain. This exciting project will pave the way for a safe, effective, and painless administration of novel therapies for the neonatal brain said Maria-Roberta Cilio, Cliniques universitaires Saint Luc.

INDENEO is one of three projects selected for funding within the Rare Diseases Research (RDR) Challenges call led by the Foundation for Rare Diseases and EJP-RD. We are very excited about this innovative project fostering public-private partnerships to drive rare disease research towards effective treatments, which is at the very heart of this European funding initiative. said Christine Fetro, Foundation for Rare Diseases.

We are enthusiastic to contribute to this European consortium. The development of nasal drug delivery systems is an important challenge for many fields of medicine, beyond the rare pediatric diseases targeted by INDENEO. said Roger Le Grand, executive director of IDMIT, CEA.

Press contact :Charlotte Reverand | cre@eveon.eu | +33 476 414 833 | @EVEON_SAS

Attachments

Read the rest here:
EVEON announces the launch of the European project INDENEO to develop an innovative delivery system for nose to brain administration of biological and...

In a recent market survey, ESOMAR-certified consulting firm Future Market Insights (FMI) forecasts an impressive growth outlook for theplatelet-rich plasma (PRP) market. The market valuation reachedUS$ 370.78 Mnin 2021 and is poised to expand at a6% CAGRthrough 2031.

Growth registered in the platelet-rich plasma market is attributable to increasing applications of PRPs in various procedures such as cosmetic, orthopedic, neurological, and maxillofacial treatments. Increasing awareness regarding the advantages of platelet-rich plasma in wound healing and tissue regeneration will further propel sales in the market.

Request for a sample https://www.futuremarketinsights.com/reports/sample/rep-gb-1722

PRP is being widely used in cosmetic surgeries aimed at improving facial structure and aesthetics, such as skin texture, and color. In addition, PRP is gaining wide acceptance as a key ingredient used in microneedling, botox treatments, acne scar removal, and laser treatments, which is spurring demand in the market.

Besides this, usage of PRPs in orthopedic treatments is fostering market sales, owing to its cost-effectiveness and negligible side effects. PRPs are increasingly finding application in joint pain treatment, cartilage reconstruction, fracture treatments, and other arthritic treatments.

With rising incidence of cosmetic procedures and sports-related injuries in countries including the U.S, the U.K., and Germany, the market is anticipated to garner significant revenue over the forecast period.

Intensive research and development, coupled with the prevalence of leading market players will further augment platelet-rich plasma market growth, with expansion at12.4%by volume.

Additionally, growing investments in healthcare infrastructure and increasing disposable income will provide tailwinds to platelet-rich plasma sales in counties such as India, China, Brazil, and South Korea, shaping the demand outlook positively.

Growing use of platelet-rich plasma in chronic wound healing, cosmetology, and orthopedic procedures, along with product innovations by leading market players will augment market growth in the upcoming years, says an FMI analyst.

Competitive Landscape

Harvest Technologies Corp., Zimmer Biomet Holdings Inc., Arthrex, Inc., Arteriocyte Medical Systems, Inc., Dr. PRP America, Cesca Therapeutics, Inc., and Regen Lab SA are among the prominent players operating in the global platelet-rich plasma market. As per FMIs analysis, tier-1 players will account for15-20%of the total market share.

Growth strategies leveraged by top manufacturers of platelet-rich plasma include strategic partnerships, mergers, acquisitions, and collaborations to launch innovative PRP treatment methods in the market. For instance:

Key Takeaways from Platelet Rich Plasma Market Survey

Ask from Market Research Expert https://www.futuremarketinsights.com/ask-question/rep-gb-1722

More Insights on the Platelet Rich Plasma Market

In its latest report, FMI offers an unbiased analysis of the global platelet-rich plasma market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (pure platelet-rich plasma, leukocyte platelet-rich plasma, leukocyte platelet-rich fibrin), origin type (autologous, homologous, and allogenic), application type (orthopedic surgery, cosmetic surgery, general surgery, neurosurgery and other surgeries including urological, cardiothoracic, periodontal, oral and maxillofacial), and across seven regions (North America, Latin America, Eastern Europe, Western Europe, Asia Pacific excluding Japan (APEJ), Japan, and Middle East & Africa).

Platelet Rich Plasma Market by CategoryBy Product Type:

By Origin Type:

By Application Type:

Explore Other Reports Links From Healthcare Market:

https://drujrake.mn.co/posts/24898121

https://tennispassion.mn.co/posts/24898141

https://skin-care-junkies.mn.co/posts/24898157

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

See the original post:
Platelet Rich Plasma Market is projected to expand at a steady 6% CAGR through 2031 - PharmiWeb.com

Stem Cell Professional market report 2020, discusses various factors driving or restraining the market, which will help the future market to grow with promising CAGR. The Stem Cell Professional market research Reports offers an extensive collection of reports on different markets covering crucial details. The report studies the competitive environment of the Stem Cell Professional market is based on company profiles and their efforts on increasing product value and production.

The research report on Stem Cell Professional market broadly covers the various factors influencing the remuneration of this industry vertical. The study also comprises of an in-depth analysis of the regional spectrum and the regulatory outlook of the said market. Additionally, the document provides with a detailed SWOT analysis as well as the market drivers impacting the overall market outlook.

Additional information regarding the challenges & limitations faced by new entrants as well as the eminent companies alongside their individual effect on the revenues of each company is highlighted. The report measures the impact of COVID-19 pandemic on the future remuneration as well as the overall expansion rate of the market.

Request Sample Copy of this Report @ https://www.newsorigins.com/request-sample/32719

Summarizing the competitive scenario of the Stem Cell Professional market:

From the regional frame of reference of Stem Cell Professional market:

Other details comprised in the Stem Cell Professional market report:

Reasons for Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a five-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

Request Customization for This Report @ https://www.newsorigins.com/request-for-customization/32719

Read the original:
Stem Cell Professional Market Professional Survey 2021 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026 - NewsOrigins

North America Is Projected To Account For The Maximum Revenue Share Of 53% In 2022.

Attributed to mounting healthcare research costs, developed countries are increasingly outsourcing biotechnology and pharmaceutical services to developing regions, especially across Asia Pacific, expected to yield substantial growth opportunities, says an analyst at Fact. MR.

Fact.MR, a market research and competitive intelligence provider: The global biotechnology and pharmaceutical services outsourcing market is anticipated to hold a market value of US$ 70 Bn in 2022 and US$ 112.31 Bn by 2032. The projected growth rate is nearly 5% during the forecast period from 2022 to 2032.

Biotechnology and pharmaceutical companies are adopting the consulting services owing to factors such as; the growing number of discrepancies in intellectual property rights and fraudulent cases. Owing to such causes, the adoption of these services is on a rise, making it a lucrative market for the players. The estimation reveals that the industry is projected to secure a market value of US$ 112.31 Bn by 2032.

Biopharmaceutical and pharmaceutical investments in novel and innovative therapies, for instance, regenerative medicine, are driving the R&D activity together with drug development services. The high demand for biologics along with small molecules has led to the expansion of service portfolios of Contract Manufacturing Organizations (CMOs)/Contract Research Organizations (CROs) for biotechnology and pharmaceutical production.

The biotechnology & pharmaceutical services outsourcing, primarily for Contract Manufacturing Organizations (CMOs) and Contract Research Organizations (CROs), has grown in popularity since last decade, and it is expected to grow in the near future. The new outsourcing industry sectors, such as rising screening services, have grown to be prosperous businesses, and many operations that were once considered essential, such as in-house spontaneous animal toxicology testing, are now rare within biotechnology & pharmaceutical services outsourcing market players.

For more insights into the Market, Get A Sample of this Report!

https://www.factmr.com/connectus/sample?flag=S&rep_id=7149

Growing Demand for Low-Cost Drug Development to Boost Medical Outsourcing

Contract research and manufacturing allow low-cost product manufacturing and development. The growing application of machine learning-based platforms such as; automation in drug manufacturing, artificial intelligence, and innovative trial designs are anticipated to transform the CMO and CRO sphere in the forecast period.

Growing pricing pressure, regulatory challenges, and patent expiration have led to shrinking margins in the biotech and pharmaceutical industry. Contract services offer cost saving to their clients and also help save time utilized in operations and management of a production & research facility. Furthermore, outsourcing services assist in overcoming trade barriers and facilitate the entry of firms into foreign markets. Owing to these advantages, several firms choose to outsource services rather than investing capital in production equipment and hiring skilled labor.

Competitive Landscape

The players of the market are focusing to increase their global influence and adopt strategies such as; acquisition, collaboration, and partnerships. Some of the recent key developments among key players are:

For Comprehensive Insights Ask An Analyst Here

https://www.factmr.com/connectus/sample?flag=AE&rep_id=7149

Key Takeaways from the Market Study

Key Market Segments Covered in the Global Biotechnology and Pharmaceutical Services Outsourcing Market

More Insights Available

Fact.MR, in its new offering, presents an unbiased analysis of the global Biotechnology & Pharmaceutical Services Outsourcing Market, presenting historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Service (Product Testing & Validation, Training & Education, Product Design & Development, Product Maintenance, Regulatory Affairs, Consulting) & research institutes and others (CROs and CMOs)) across six major regions (North America, Latin America, Europe, East Asia, South Asia & Oceania and Middle East & Africa).

Get Customization on this Report for Specific Research Solutions

https://www.factmr.com/connectus/sample?flag=RC&rep_id=7149

Fact.MRs Domain Knowledge in Healthcare

Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.

Check out more studies related to Healthcare Industry, conducted by Fact.MR:

Clear Aligners Market - Clear Aligners Market by Age (Adults, Teens), End-User (Hospitals, Standalone Practices, Group Practices, Other End-Users), and by Region- 2022 to 2032

Non-Invasive Aesthetic Treatment Market - Global Non-Invasive Aesthetic Treatment Market by Procedure (Injectables, Skin Rejuvenation, Other Procedures), End User (Hospital/ Surgery Center, MedSpa, Traditional Spa, HCP Owned Clinic) and by Region- 2022 to 2032

Sacroiliac Joint Fusion Market - Sacroiliac Joint Fusion Market Analysis by Indication (Degenerative Sacroiliitis, Sacral Disruption, Trauma), by Treatment Type (Sacroiliac Joint Fusion Surgery, Sacroiliac Joint Fusion Injections, RF Sacroiliac Joint Fusion Ablation), by End User & Regional Forecast 2022-2032

Skincare Devices Market - Skincare Devices Market Analysis by Product (Diagnostic Devices, Treatment Devices), by Application (Diagnostic Devices, Treatment Devices), by End Use (Hospitals, Clinics, Others) and by Region- 2022 to 2032

Orthopedic Power Tools Market - Orthopedic Power Tools Market Forecast, Trend Analysis & Competition Tracking - Global Market insights 2017 to 2026

Dermatology CRO Market - Dermatology CRO Market by Type (Drug Discovery, Clinical, Preclinical), by Service (Project Management, Data Management, Medical Affairs, Medical Writing, Clinical Monitoring, Quality Management, Bio-statistics, Investigator Payments, Laboratory, Patient and Site Recruitment, Technology, Other Services), and Region - 2022 to 2032

Basin, Bowl and Cup Market - Basin, Bowl and Cup Market Analysis by Type (Basin, Bowl, Cup), by Material Type (Plastic (Polypropylene), Stainless steel), by End-user, Global Forecast 2022-2032

Cardiac Resynchronization Therapy Market - Cardiac Resynchronization Therapy Market Analysis by Product Type (CRT-Defibrillator, RT-Pacemaker), by End-user Type, by Region - Global Forecast 2022-2032

Home Infusion Therapy Market - Home Infusion Therapy Market by product (infusion pumps, intravenous sets, IV cannulas and needleless connectors) application (anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, specialty pharmaceuticals and other applications), and by Region- 2022 to 2032

Blood Ketone Meter Market - Blood Ketone Meter Market by Product Type (Blood Ketone Monitoring, Blood Glucose and Ketone Monitoring, Consumables), Application (Human, Veterinary), End-use, and Region -2022 to 2032

About Us:

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and well be an able research partner.

Contact:

Mahendra Singh

US Sales Office:

11140 Rockville Pike

Suite 400

Rockville, MD 20852

Email: sales@factmr.com

Tel: +1 (628) 251-158

More here:
Global Biotechnology & Pharmaceutical Services Outsourcing Market Is Expected To Grow At A CAGR Of 5% From 2022 To 2030 To Reach US$ 112.31 Bn by...

Global Amniotic Membrane Market Share, Size, Industry Report with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume and value related cross segmented information by each country. The report offers a comprehensive evaluation of the Amniotic Membrane market. It does so via in-depth Amniotic Membrane qualitative insights, Amniotic Membrane historical data, and Amniotic Membrane verifiable projections about market size. The Amniotic Membrane projections featured in the report have been derived using proven research methodologies and assumptions

Amniotic Membrane Market is valued at USD 906.4 Million in 2018 and expected to reach USD 1800.3 Million by 2025 with CAGR of 10.3% over the forecast period.

Market Analysis of Amniotic Membrane-

The amnion is the innermost layer of the placenta and used for wound healing mainly due to its bacteriostatic and pain reduction properties. Rising awareness in the recent past has led to a surge in the number of transplants leading to increasing demand for these tissue-based products. It has also led to a rise in the number of donations thus, propelling the market growth. Typically, amniotic membranes are used for indications, such as pterygium excisions, reconstruction of the conjunctiva surface, corneal ulcers, surgical wounds, pressure and venous leg ulcers, regenerative medicine, and limbal stem cell deficiency. Amniotic membrane transplant is a better alternative for corneal and conjunctival reconstruction. It is used in ophthalmology for the treatment of a number of conditions, such as cicatricial pemphigoid and Stevens-Johnson syndrome; pterygium; persistent epithelial defects with ulceration; conjunctival surface reconstruction; and ocular surface reconstruction in patients with chemical and thermal burns.

Segmentation Analysis:

By Application:

By Product:

By End-User:

Get Sample PDF Report with Graphs and Figures @ https://brandessenceresearch.com/requestSample/PostId/445?Desiner_Guru

Some of the key players/Manufacturers involved in the Market are:

Applied Biologics LLC, Amnio Technology, LLC, Alliqua BioMedical, Inc., FzioMed, Inc., Human Regenerative Technologies, LLC, Skye Biologics Inc., IOP Ophthalmics, Amniox Medical, Inc., Derma Sciences Inc., and MiMedx Group, Inc. and Others.

Important years considered in the study are:

Historical year 2015-2020; Base year 2020; Forecast period** 2022 to 2028

Amniotic Membrane Market Report is also available for any Specific Regions & Countries:

Chapter 1- Report Methodology

1.1. Research Process

1.2. Primary Research

1.3. Secondary Research

1.4. Market Size Estimates

1.5. Data Triangulation

1.6. Forecast Model

1.7. USPs of Report

1.8. Report Description

Chapter 2 Global Amniotic Membrane Market Overview

2.1. Market Introduction

2.2. Executive Summary

2.3. Global Amniotic Membrane Market Classification

2.4. Market Drivers

2.5. Market Restraints

2.6. Market Opportunity

2.7. Amniotic Membrane Market: Trends

2.8. Porters Five Forces Analysis

2.9. Market Attractiveness Analysis

Continued@..

Browse Full Report Description, TOC & List of Facts & Figures @ https://brandessenceresearch.com/requestSample/PostId/445?Desiner_Guru

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contect Us:

Email: vishal@brandessenceresearch.com

Email: Sales@brandessenceresearch.com

Corporate Sales: +44-2038074155

Asia Office: +917447409162

Website: https://brandessenceresearch.com

Trending Reports:

See the rest here:
Amniotic Membrane Market Is Expected to Witness with Strong Growth rate in the forecast period (2022 to 2028) Designer Women - Designer Women

Potion of Blindness

Potion ID

15

Effect

Blindness

Ingredients

Nether Wart, Ink Sac, Golden Carrot, Fermented Spider Eye

First Appearance

N/A

Type

Potion

Idea Designer

TheDevinGreat

Potion of Blindness is a potion that will create a thick block void-like fog around the player. It can be brewed by adding a Fermented Spider Eye to a Night Vision potion, or adding Ink Sac to an Akward Potion. And can be used as defense against hostile mobs, since they will be unable to find the player or what's ahead of them when a splash potion. But don't thow it too close or you will experience Blindness the same as that mob. It can be cured by drinking milk, or waiting the time that the effect lasts.

It can be brewed in 2 ways. (Not really in Minecraft.)

Akward Potion - Golden Carrot - Fermented Spider Eye

Akward Potion - Ink Sac

Read the original post:
Potion of Blindness | Minecraft Ideas Wiki | Fandom

Jack Levine| Guest columnist

My dad was 60 when I was born. Not only was he the oldest dad on the block, he was older than all of my friends' grandfathers. He was alsoblind, having lost his sight in his early 50s. He suddenly wentblind in the 1940s, after having a few days of blurry vision. The doctors guessed it was vascular, perhaps an aneurysm on the optic nerve.

It's said that when one sense goes the others perk up a bit. Well, eight years after my dad went blind, I came along; some things in life don't require good sight!

Growing up with a blind dad wasn't easy. Sometimes his blindness frightened me. On occasion I would play blind, walking through a room with my eyes tightly shut, feeling my way with outstretched arms and walking in a halting gait, wondering how my dad managed to move around with such effortless grace.

Beginning at age nine it was my responsibility to read for my dad mostly newspaper columns and editorials focused on civil rights reform.

He listened patiently as I struggled through the tough words andhad to spell out a few. But I'll never forget the light that would shine from his blind eyes when I learned anew fact or a fresh angle on an issue of concern. When that light went on, I knew I was doing a good job. He couldn't see my smile but I knew he sensed it.

My dad never went to school a single day in his life. He was an immigrant who came to this country at the turn of the century to escape the tyranny of forced "conscription" in the Imperial Russian Army. The teenage boys gathered from the shtetls were not formallyrecruited or given uniforms. They were forced to run through the woods, used as human target practice, to hone the skills of Cossack sharpshooters.

Those who survived feigned death and crawled back to the village to warn the others (like my father) to run away and escape to the West.

He and a friend, Benny, left their families at age 14, working their way through Poland over a three-year period to save enough to board a ship in Danzig (now Gdansk) for the New World … for survival and to be free.

My dad spoke five languages and later in life mastered Braille, but was versed in the language of politics the best. He believed it was politics that forced those young kids to run through the woods as human prey. It was also politics and policies thatinfluenced every stage of his life.

My dad never hesitated to share his personal stories and his generation's history. Most of my knowledge of the 20th century is rooted in his accounts of life's struggles, successesand failures.

On Father's Day, I think of how different my childhood would have been if I had a different father. One who was not blind, who could play catch, take me to a movie,or compliment my drawings.

Yet, I know I was enriched by being with a wise old man, helping to narrate his life's events. For as long as I can remember, I saw for two people. That was both an obligation and an opportunity.

Every memory is a subjective vision of the past. All of us recall our childhoods with a blend of joy and regret;pleasure balanced with pain.

Some of us never really knew our fathers lost to war, alcohol abuseor abandonment. Some feared their father's anger or coldness but deeply respected his hard work and dedication to family. Some men live up to what's expected of them, others stumble, yet few do not try to do their best.

It has been more than 40 years since his death, and I think of Fathers Day as a chance to cherish the gifts he gave me that had no wrapping paper. I believe his influence lives in the work I do, my appreciation of others' challengesand the relationship I have built with mytwo sons, who never got to meet the old guy with the gray beard and bright, shining eyes.

I implore you to think of the life lessons we've learned good or bad from our fathers. Let's honor them by emulating the good, overcoming the badand sending a signal to our children (in both word and action)that they are valued.

Jack Levine, founder of the 4Generations Institute, is a Tallahassee-based family policy advocate. He may be reached at jack@4gen.org.

This guest column is the opinion of the author and does not necessarily represent the views of the Times-Union. We welcome a diversity of opinions.

More here:
Jack Levine: Remembering a dad who proved that even in blindness, there can be vision - The Florida Times-Union

Scientists in Europe have discovered a molecular zipper mechanism that can lead to cell death in the genetic disease retinitis pigmentosa. The good news is that injecting certain proteins could slow down or prevent vision impairment from the disease.

Retinitis pigmentosa is a relatively common hereditary disease that affects the photoreceptors, cells in the eye that register light. As they degenerate, patients will start to lose their night vision and peripheral vision, and over decades can become partially or completely blind. Unfortunately, there are few treatment options.

Photoreceptor cells are tiny and complicated, making it difficult to tell exactly whats going on in there as the disease progresses. So for the new study, the team used an emerging technique known as expansion microscopy to inflate cells without deforming them, allowing retinal tissue to be examined at a higher resolution than ever before.

The scientists focused on a component of the photoreceptors known as the connecting cilia, which links the outer, light-sensitive pigments of the cell to the machinery that converts that light into nerve signals. This connecting cilia has been implicated in retinitis pigmentosa, but what that role is has remained a mystery.

Using expansion microscopy, the team identified that four proteins drive a series of microtubules to stick together in a kind of zipper formation, which holds the cilia together. But when the gene that codes for one of these proteins, called FAM161A, has a particular mutation, those microtubules dont zip up as tightly. Over time, they unravel and eventually collapse, which kills off the photoreceptors, causing the vision impairment associated with retinitis pigmentosa.

While this work is mostly foundational in improving our understanding of how the disease occurs, the team says that it could also inform new potential treatments to prevent cell death and vision impairment. One idea will be evaluated in follow-up work.

By injecting the protein into patients suffering from certain types of retinitis pigmentosa, we can imagine that the molecular zipper could be restored to ensure the structural integrity of the microtubules of the connecting cilia, thus preventing the death of photoreceptor cells, said Paul Guichard, co-author of the study.

The research was published in the journal PLOS Biology.

Source: Universit de Genve

More here:
Tightening a molecular "zipper" could help prevent hereditary blindness - New Atlas

Glaucoma is a vision condition that results from damage to your optic nerve, often due to elevated pressure in the eye. Its one of the most common causes of vision loss in adults and can lead to blindness without treatment.

Eye drops and other treatments can cause dry eyes in many people with glaucoma. People who have glaucoma might already be at heightened risk for developing dry eyes because the conditions share some risk factors.

Dry eyes can be chronic and uncomfortable, interfering with daily life. Its possible to treat both glaucoma and dry eyes with a combination approach. Well overview the link between these conditions, symptoms, and available treatment options.

Its common for dry eye and glaucoma to occur together. Dry eye is a type of ocular surface disease (OSD), which also includes blepharitis (eyelid inflammation).

2020 research states the global prevalence of OSD in people with glaucoma is around 40 to 59 percent, substantially higher than the general population.

There are a few reasons for this, including:

Dry eye and glaucoma can be difficult to treat. Although dry eye is often more painful and irritating for the patient, glaucoma is a more serious condition as it can lead to blindness. Because of this, eye doctors will focus on treating glaucoma first, even if that makes relief of dry eyes more difficult.

However, your doctor will do their best to ensure both dry eye and glaucoma are treated for the best quality of life outcome.

Glaucoma is the name for a group of conditions that cause damage to the nerves in your eyes. Glaucoma results in vision loss and can lead to blindness without treatment. It can occur in one or both eyes.

Medical researchers have long thought that glaucoma only occurred when the pressure built up inside the eyes. Newer research indicates that glaucoma can develop even when the pressure inside the eyes is normal.

Glaucoma doesnt always cause symptoms early on, so people are often unaware they have it in the early stages. This is especially true if you have a type of glaucoma called open-angle glaucoma. About 90 percent of people with glaucoma have this type, and its the second leading cause of legal blindness in the U.S.

When symptoms of any type of glaucoma develop, they may include:

While its possible to slow or stop the progression of glaucoma, any vision loss caused by glaucoma is irreversible. Detecting glaucoma early and getting treatment quickly can prevent blindness. Its important to see an eye doctor as soon as possible if you have any glaucoma symptoms.

Glaucoma can be screened for and detected by a routine eye exam with your ophthalmologist. The American Academy of Ophthalmology (AAO) advises adults have a comprehensive medical eye examination at age 40 if they havent had one yet.

Dry eye is a common eye condition. It happens when your eyes cant make enough tears, or when the tears your eyes make dont keep your eyes moist enough. When your eyes arent well moisturized, they can become uncomfortable and inflamed.

In some cases, dry eye is temporary. For example, you might get a flare of dry eye from being outside on a very windy day, or from a long shift of computer work. In other cases, dry eye can be a chronic condition.

Dry eye can be very irritating and can make it difficult to complete everyday tasks. Especially when chronic, dry eye can have far-reaching impacts on your quality of life.

Symptoms of dry eye can include:

Some people with dry eyes may experience discharge from their eyes or eyelids. Discharge can also be a sign of eye infection.

Some cases of night vision can be treated with over-the-counter eye drops. However, prescription-strength treatment and lifestyle changes can help many people.

Youll likely need a combination of treatments to help both dry eye and glaucoma. You might go through several treatment options until you find the combination that is most helpful for your eyes.

According to NIH and AAO, treatment approaches include:

Your doctor might also recommend lifestyle changes, such as:

Factors that are unrelated to glaucoma can also cause dry eye. Sometimes these factors can occur alongside glaucoma and can make treating it more challenging.

Dry eye and glaucoma commonly occur together. They share risk factors such as age and having diabetes, and some glaucoma treatments can cause dry eye.

Treating both conditions together can be challenging. While dry eye may be more painful and difficult to deal with in the short term, glaucoma is more dangerous to your vision in the long term. This means glaucoma treatment will be prioritized.

However, doctors will always attempt to treat both conditions. In most cases, youll receive a combination of treatment approaches that can help preserve your vision and restore your eye comfort.

Read the original here:
What's the Link Between Glaucoma and Dry Eyes? - Healthline

Lisa Durden, an award-winning director/producer and media personality leads the production of Blind Divas, a documentary following Krystle Allen and Naquela Wright-Prevoe, two blind, Black women entrepreneurs, determined to challenge the stigmas and stereotypes about the blindness community. This is not just a story about two determined women who are everyday champions in the blindness community, its also a story of triumph.

Durden, Allen and Wright-Prevoe joined WBGO Journal host and News Director Doug Doyle to talk about the project and what ahead.

Durden says this film will pull back the curtain of curiosity about the abilities of women with vision loss, as we document their national Finding Miss Blind Diva Tour; Hosted by Eyes Like Mine Inc. and the Greater Vision Foundation, The Miss Blind Diva Empowerment Pageant is honoring marvelous moms with disabilities. Join them for an afternoon of empowerment, entertainment, giveaways, and more.

Here are some of the upcoming events :June 25, 2022 - Community Baby Shower, Newark, NJ July 5-10, 2022 - National Federation of the Blind National Convention,New Orleans, Louisiana, LA

For her focus on this compelling story, Lisa Durden, was the WINNER of the national short documentary pitch competition, sponsored by African American Women in Cinema Film Festival (AAWIC), in collaboration with the distributor, Lightbeam TV; A streaming platform featuring stories that shine a light on inspiring people and organizations making the world a better, more hopeful place.

Lisa Durden earned her Masters In Fine Arts Degree, in Social Documentary Film, from New Yorks School Of Visual Arts. Ms. Durden took the leap and launched Lisa Durden Unlimited Productions, a Multi-Media Company, specializing in developing content for linear television, film, digital and live audiences, with a focus on telling compelling stories about underserved communities, featuring big, entertaining, characters.

Some of Ms. Durdens award-winning projects include: Director/Producer, short documentaryGirls Matter, which WON Best Animation at the Tokyo International Short Film Festival 21;Assistant Director of the VerizonCommercial,Conversations With Mom; Producer of award-winning PBS 2019 Online FestivalShortFilm,Paris Blues in Harlem; Senior Producer of ImageNations star studded Revolution Awards; Co-Producer of the provocative, award-winning, feature filmTITLE VII; Conceived & ProducedPBSMaya Angelou Films successful Live Twitter Chat, which garnered 8 Million Impressions; The former Broadcast Manager with the Black Public Media,AfroPoP Series; Associate Producer of PBS documentary, Soul Food Junkies; and Associate Producer of Peabody award-winning, Prime-Time Emmy and NAACP Image awards nominated, Sundance Channels, docu-series, Brick City 1.

You can SEE the entire interview here.

See the rest here:
Lisa Durden's upcoming documentary "Blind Divas" follows Krystle Allen and Naquela Wright-Prevoe, two Black women entrepreneurs, determined...

Monday night, two neighbors and I enjoyed each others company and conversation around a backyard fire to celebrate the summer solstice.

Politics came up. One neighbor said she didnt think Joe Biden legitimately won the 2020 presidential election. The other said he didnt think too many people were paying much attention to the House select committees historic hearings about the Jan. 6, 2021 riot at the U.S. Capitol.

I did not argue with my neighbors or try to persuade them to change their minds. I asked what they thought of Rep. Adam Kinzinger and Vice President Mike Pence, Republicans who refused to go along with President Donald Trumps plot to overturn results of a free and fair election.

RINOs, the one neighbor said, meaning Republicans In Name Only. Many share her view that loyalty to the GOP matters more than oaths sworn to uphold the U.S. Constitution.

The House committee is building its case to the American people. Through witness testimony, documents, emails, text messages, video and other evidence, the committee is showing how Trump tried to stay in office despite losing the popular vote to Biden by about 7 million votes.

Trumps lust for the power drove him to convince millions of his followers that the 2020 election was fraudulent. Former New York City Mayor Rudy Giuliani, Fox News hosts and other influential people publicly went along with the scheme. The committee has heard from former U.S. Attorney General Bill Barr and others, who testified they repeatedly told Trump his ploy was illegal.

If fraud had occurred, Trumps proper recourse was to plead his case in court. His supporters filed more than 60 lawsuits in state and federal courts, but no one could present any evidence of fraud, only lies and hearsay. Judges, including some appointed by Trump, dismissed the cases.

Trumps unwillingness to accept the reality of his loss may involve a concept known as willful blindness, legal analysts have written. Trump himself might have believed there was fraud, but testimony shows he refused to listen to anyone who told him the evidence said Bidens win was legitimate.

To this day, many Republican voters and elected officials refuse to publicly admit Biden won the presidency. Many believe fictional stories about mules harvesting illegal votes cast by purported dead people or immigrants. Theyve been told to believe electronic voting equipment was somehow manipulated to favor Biden.

The false narratives collectively known as Trumps big lie cast doubt on the integrity of our voting systems and democracy.

Not only is Trump willfully blind, the hearings show that millions of fellow Americans deliberately refuse to acknowledge mounting evidence that violence at the Capitol that day was no accident. Rather, it was the culmination of an illegal ploy to halt the certification of Electoral College results.

Insurrectionists loyal to President Donald Trump breach the Capitol in Washington, D.C. Jan. 6, 2021. (AP Photo/John Minchillo/AP)

Trump embraced the plan to violently overturn the outcome, but Pence refused to go along with the scheme. There was no legal basis to a cockamamie theory that the vice president could reject the will of voters by legitimizing slates of phony electors in several swing states that Trump lost.

The plan was to kick Electoral College slates back to certain states where Republicans held legislative majorities. The scheme never made it that far. Our institutions held, but barely. You may recall 121 House Republicans and six GOP senators voted to reject results from Arizona.

Americans who ignore the truth of Jan. 6 use mental gymnastics to create an alternate reality. They deny evidence. They deflect by talking about gas prices or other concerns. They try to discredit those presenting evidence by calling the effort to seek accountability a partisan witch hunt.

The select committees important task is to show Americans that the threat to democracy is ongoing. Last week, a Republican-led county commission in New Mexico relented and voted to certify election results after initially refusing to do so. The states supreme court ordered the panel to certify results that the commission initially rejected due to unfounded conspiracy theories, Reuters reported.

Our institutions held in late 2020 and early 2021 because enough people of integrity were in positions to refuse to go along with illegal schemes to overturn election results. Now there are fewer people of integrity left in gatekeeper positions. Some left amid threats and intimidation.

Rep. Adam Kinzinger, R-Ill., listens Tuesday as the House select committee investigating the Jan. 6 attack on the U.S. Capitol continues to reveal its findings of a year-long investigation. (AP Photo/Jacquelyn Martin/AP)

Twice-weekly

News updates from the south suburbs delivered every Monday and Wednesday

Kinzinger on Sunday shared a letter he received at his home in Channahon. The writer threatened to execute the congressman, his wife and their 5-month-old child because of the Republicans efforts to uphold democracy.

The Darkness is spreading courtesy of cowardly leaders fearful of truth, Kinzinger wrote on Twitter. The threats Ive gotten dont scare me. They make me more determined.

Many are concerned insurrectionists will try again in 2024 to overturn election results if they disagree with the outcome. Evidence of the ongoing plot to destroy our democracy ought to strengthen the resolve of every American to vote and exercise their rights.

The battle for American democracy reminds me of The Skin of Our Teeth, a 1942 play by Thornton Wilder. We have always faced existential threats, and have barely survived many of them. Fascism, nuclear war and economic collapse, to name a few.

Somehow weve pulled through, sometimes by razor-thin margins. Whatever the future holds, I expect it will be close. A few votes here and there could make a world of difference.

Ted Slowik is a columnist for the Daily Southtown.

tslowik@tribpub.com

See more here:
Trump election lies may fit legal concept of willful blindness - Chicago Tribune

From Charity Nwakaudu, Abuja

In its global fight against poverty and avoidable blindness, an international organization, Sightsavers, has relaunced its thematic strategy to ensure that it reaches out to those affected and support their overall health system.

Speaking in Abuja, NIgeria, Country Director Sightsavers , Dr Sunday Ishiyaku stated that as part of strategies towards achieving its goals, the organization has developed capacities by making investments in growth and learning to ensure that there are adequate resources to tackling a wide range of complex diseases more innovatively and strategically premised on system strengthening to drive sustainability.

Ishiyaku noted that the strategy was conceived as a five- year framework with four major change theme such as Health, Education, Social inclusion, Community participation and development as well as eye health programmed.

He said that as an organization, it was working hard to prevent unavoidable blindness whilst also ensuring that those with disabilities participate equally in the Society.

We are a global organization working in more than 30 countries in African and Asian continents to prevent avoidable blindness whilst ensuring that those with disabilities participate equally in the society.

Sightsavers started out as an international service delivery- oriented charity and this was the case until 2009 when it transited into an international development organization requiring that it looked at tackling a wide range of complex diseases.

In the years covering the strategy (2009-2019), Sightsavers was committed to implementing its ambitious strategy that includes four major themes i.e eye health, education, social inclusion and community development and participation.

The Country Director explained that in the renewed global efforts to leave no one behind, Sightsavers also initiated the Sustainable Development Goals ( Agenda 2023), with the specific inclusion of an Neglected Tropical Diseases, NTD, target in SDG3.

Launching the Sightsavers thematic strategy virtually, Vice President, Board of Trustees, Sightsavers, Professor Uche Amazigo pointed out that its essence was to achieve the vision of a world where no one is blind from avoidable causes and where people with disabilities could participate equally in the society.

She that research has shown that there were almost 2 billion people suffering from blindness or partial impairment and Nigeria was with the highest number in this group hence the need for this alliance, adding that we should imagine a Nigeria with positive change in education, champions of Child Rights.

Read the rest here:
Sightsavers relaunches its thematic strategy The Sun Nigeria - Daily Sun

The World Health Organization (WHO) today welcomed the announcement by Pfizer Inc. that it will extend its donation of the antibiotic Zithromax (azithromycin) for trachoma elimination until 2030, building on the companys 23-year commitment to fight the worlds leading infectious cause of blindness.

Caused by repeated bacterial infection of the eyes, trachoma blinds the poorest people in the world. WHO recommends a four-part strategy to eliminate trachoma as a public health problem. This strategy takes the acronym SAFE, representing: surgery for advanced disease, antibiotics to clear infection, and facial cleanliness and environmental improvement (particularly increased access to water and sanitation) to reduce transmission. Pfizers Zithromax donation is a critical part of SAFE, and is managed by the International Trachoma Initiative at the Task Force for Global Health, Decatur (GA), USA, an organization in official relations with WHO.

Continuing the donation programme will bring relief to millions of people around the world who are affected by this preventable neglected tropical disease, said Dr Ren Minghui, WHOs Assistant Director-General for Universal Health Coverage/Communicable and Noncommunicable Diseases. WHO is very grateful for Pfizers ongoing commitment to helping prevent trachomatous blindness.

Caroline Roan, Senior Vice-President Global Health & Patient Impact, Pfizer Inc., commented, Trachoma is a debilitating disease that should no longer wreak havoc on peoples lives and livelihoods. We are proud to support our longstanding trachoma partners working tirelessly towards elimination and improving lives worldwide.

Between 2002 and 2021, due to a combination of SAFE strategy implementation, improved living conditions and better data, the estimated number of people living in trachoma-endemic areas worldwide fell 91% from 1517 million to 136 million. But over the past 2 years, the coronavirus disease (COVID-19) pandemic has limited the activity of programmes against neglected tropical diseases in many countries. Community-based work, such as antibiotic mass drug administration for trachoma, has been particularly adversely affected.

In the road map for neglected tropical diseases 20212030, endorsed by the World Health Assembly in November 2020, trachoma is targeted for global elimination as a public health problem by 2030. To date, 13 countries (Cambodia, China, the Islamic Republic of Iran, the Lao Peoples Democratic Republic, the Gambia, Ghana, Mexico, Morocco, Myanmar, Nepal, Oman, Saudi Arabia and Togo) have been validated as having achieved this milestone.

Follow this link:
Trachoma elimination: millions more to benefit from donated azithromycin - World Health Organization

A new strain of super gonorrhoea has been reported after an Austrian man had unprotected sex with a Cambodian sex worker.

What makes this strain so worrying is that it is resistant to most antibiotics commonly used to treat the infection, scientists have warned.

Adding to this risk, experts have cited that if multidrug-resistant strains of gonorrhoea keep spreading, many cases of the STD might become untreatable.

This was highlighted in a study published recently in the medical journal Eurosurveillance, part of the European Centre for Disease Prevention and Control.

The disease is caused by the bacterium called Neisseria gonorrhoeae.

The infection is spread by unprotected vaginal, oral and anal sex.

Lead author of the report, Dr Sonja Pleininger of the Austrian Agency for Health and Food Safety, said such a strain poses a major global public health threat.

If such strains manage to establish a sustained transmission, many gonorrhoea cases might become untreatable, she added.

The unidentified Austrian man in his 50s complained of unusual symptoms five days after his sexual encounter.

His symptoms reported included pain while peeing and a discharge coming out of his penis.

The man was initially treated with azithromycin and ceftriaxone.

Two weeks later, his symptoms resolved, but a penile swab showed he still had gonorrhoea.

Tests showed his "super" bug was still immune to treatment.

Typical symptoms of gonorrhoea include a thick green or yellow discharge from the vagina or penis, pain when peeing and, in women, bleeding between periods, warns the NHS.

The national health body added: But around one in 10 infected men and almost half of infected women do not experience any symptoms.

The bacteria that cause gonorrhoea are mainly found in discharge from the penis and in vaginal fluid.

In women, it can lead to pelvic inflammatory disease, which could cause problems with fertility and future pregnancy.

It may also increase the risk of ectopic pregnancy, a medical emergency.

Gonorrhoea can also increase the risk of transmitting or acquiring HIV.

According to Dr Teodara Wi, World Health Organisations (WHO) medical officer specialising in STIs, other serious risks of super gonorrhoea include:

See the rest here:
Dangers of super gonorrhoea from infertility to blindness as global warning issued - Daily Star

Jen Patja Howell shared an episode of the Lawfare Podcast in which Benjamin Wittes Wittes sat down on Twitter Spaces with Roger Parloff, Quinta Jurecic, and Molly Reynolds to discuss day four of the Jan. 6 committee hearings:

She alsoshared an episode of the Lawfare Podcast in which Wittes talked with Jurecic, Parloff, and Katie Benner of the New York Times about day five of the Jan. 6 select committee hearings:

Pollard shared a livestream of day four of the Jan. 6 select committee hearings. He also shared a livestream of day five of the Jan. 6 select committee hearings.

Elena Kagan shared an episode of Lawfare No Bull which features audio from the fourth public hearing held by the Jan. 6 select committee:

Bob Bauer argued that presidents seeking reelection can pose unique challenges to democratic elections in situations in which their desire to win can lead to disastrous results.

Daniel Richman discussed the role that the doctrine of willful blindness might have in proving Trumps criminal liability if a case were brought against the former president for his role in the Jan. 6 Capitol attack.

David Priess shared an episode of Chatter in which Shane Harris sat down with Tim Naftali to discuss the legacy of Watergate in light of the Jan. 6 Capitol attack:

Howell shared an episode of the Lawfare Podcast from the November 2020 archives in which Evelyn Douek and Jurecic sat down with Alex Stamos to discuss the state of election security and the difficulty of countering false election claims:

Robert Chesney and Steve Vladeck shared an episode of the National Security Law Podcast in which they discussed the latest Jan. 6 conspiracy indictment, the Navarro contempt of Congress charge, the lawsuits challenging the Texas and Florida social media content-moderation laws, and more:

Stewart Baker shared an episode of the Cyberlaw Podcast in which he sat down with Amy Gajda to discuss her book, Seek and Hide: The Tangled History of the Right to Privacy:

Baker shared another episode of the Cyberlaw Podcast in which he sat down with Matthew Heiman, Scott Shapiro, and Nick Weaver to discuss the bipartisan effort to transform the Committee on Foreign Investment in the United States, cryptocurrency firms on the verge of collapse, TikTok, and more:

Herb Lin discussed the functional trade-offs in baked-in cybersecurity in product management.

Susan Landau argued that the EU proposal on combating child sexual abuse material online could present national security problems and relies on technology that does not exist yet.

Steve Bunnell reviewed James E. Bakers The Centaurs Dilemma: National Security Law for the Coming AI Revolution (Brookings Institution, 2020).

Howell shared an episode of the Lawfare Podcast in which Wittes sat down with Asfandyar Mir and Daniel Byman to discuss the current position of al-Qaeda in the world:

Howell also shared an episode of Rational Security in which Alan Rozenshtein, Jurecic, and Scott R. Anderson sat down to discuss the extradition of Julian Assange, Chinese access to TikTok customer data, and Googles potentially sentient LaMDA artificial intelligence program:

Jordan Schneider shared an episode of ChinaTalk in which he sat down with Weijian Shan to discuss Shans personal story of exile during the Cultural Revolution and his view on Chinas economic transformation:

Anoush Baghdassarian analyzed recent cases from the International Court of Justice that Armenia and Azerbaijan each brought against one other for alleged violations of the International Convention on the Elimination of All Forms of Racial Discrimination.

Max Johnston and Bryce Klehm shared the final episode of Allies, which they discuss the uncertain long-term legal status of Mahnaz, a former member of the Afghan militarys Female Tactical Platoon, and other Afghans who are on parole after coming to the U.S. during the U.S.s withdrawal from Afghanistan:

Matthew Tokson discussed what a recent ruling from the First Circuit means for Fourth Amendment cases concerning the use of telephone pole cameras for surveillance purposes.

Kyleanne Hunter discussed the potential impacts that overturning Roe v. Wade would have on women in uniform.

And Hyemin Han and Katherine Pompilio shared an application for the fall 2022 Lawfare internship.

And that was the week that was.

See the article here:
The Week That Was: All of Lawfare in One Post - Lawfare - Lawfare

How the illusion of a post-queer society let actor Rebel Wilson down.

Its been nearly two weeks since we heard the Sydney Morning Herald had a hand in making the actor Rebel Wilson reveal she was dating another woman.But as the news cycle swiftly barrels on, there are questions that continue to linger.

Namely, how could reporter Andrew Hornery and editor Bevan Shields who are both gay not understand that threatening to reveal a celebritys first same-sex relationship is an inherently harmful idea? How could they have been so blind?

Thats the theme that kept sticking out to me: sustained, wilful blindness. Blindness to the fact that we continue to inhabit a culture where queer people are marginalised, regardless of how many legal gains may have been made.

As both Hornery and Shields pushed out their articles over the weekend, at first furiously agreeing with each other before conceding that some harm may have been done, there was a common through-line: Both went out of their way to use non-gendered language. Rebel was simply in a new relationship; Ramona Agruma was her new partner, they were simply trying to break the news of this celebrity romance.

Both men seemed desperate to ignore the elephant in the room Rebel Wilson, an actress who most people know as straight, was in a same-sex relationship. And Hornerys email, regardless of what he intended, threatened to out her.

I couldnt help but be reminded of the problem of colour-blindness; the people who insist they dont see race, a narrative captured in the platitude, theres only one race, the human race. Its this same spirit that permeated the Sydney Morning Heralds recent festival of cluelessness, but this time, it wasnt colour blindness, but its LGBTIQ analogue: queer blindfolding.

In the way that colour-blindness perpetuates racism by denying the existence of white privilege, queer blindfolding is the process of perpetuating homophobia by not acknowledging it exists. The concept was coined by US researchers Richard Shin and Lance Smith, who define it as well-intentioned heterosexual identifying individuals that results in the disappearing of queer identities. And while straight people probably thinks that theyre doing a good thing by ignoring a persons sexuality were all just people, are we not? the narrative comes with pernicious consequences.

Namely, adopting the ideology of queer blindfolding can result in minimising or even denying the marginalisation that is experienced by those who identify as queer. And in my opinion, it is this wilfully blind way of looking at the world that has contributed to the Sydney Morning Heraldunknowingly threatening Wilson with an ultimatum.

Both Andrew Hornery and Bevan Shields used language that indicated that they were fans of this school of thought. Consider the following turns of phrase: [We] asked Wilson if she wished to comment about her new partner, wrote Bevan Shields in his initial supportive response to Andrew Hornerys first article. We would have asked the same questions had Wilsons new partner been a man.

Similarly, in Hornerys (now deleted) initial article, he was at a loss as to why a woman who previously used to brag about her handsome ex-boyfriend wouldnt do the same with her same girlfriend. Of course, who anyone dates is their business, but Wilson happily fed such prurient interest when she had a hunky boyfriend on her arm, he adds.

Here, both Shields and Hornery are taking the bizarre stance that when youre a woman, having a girlfriend is equally as socially acceptable as having a boyfriend.

And that, in a nutshell, is clear blindfolding: wilfully ignoring the heterosexism that we swim in every day.

While Shin and Smith point out that heterosexual attitudes toward LGBTIQ folks are generally improving, were not exactly in some post-gay utopia. Heterosexuality is obviously the dominant sexual orientation in our culture. Take, for example, the fact that most love stories in our culture involve cis-gendered men and cis-gendered women; the fact that we assume people are straight by default; and that a fear of abuse still means that many queer people hide their sexuality at work.

Or the teacher who was sacked because of their sexuality in 2021, or the constant targeting of trans peopleduring the lead-up to the federal election. Or the current horrendous discourse around trans participation in elite swimming. Just the simple fact that straight people dont need to come out tells you that straight people and queer people are obviously not on a level playing field.

And yet, we get Hornery coming out with the astonishing take that thanks to decades of battling for equality sexual orientation is no longer something to be hidden, even in Hollywood, adding that same-sex marriage is legal in many parts of the world, as though Wilson, by not publicly coming out to the entire world right away, is being overly dramatic or creating a problem that isnt there.

They are. Both reporter Andrew Hornery and editor Bevan Shields identify as gay men. But while Shin and Smith say that its heterosexual identifying people who are prone to queer blindfolding, queer folks arent immune to taking on the same.

In particular, studies have found its not uncommon for gay men who are white, cis-gendered, and affluent to use queer blindfolding as a narrative strategy. Those who inhabit other marginalised identities, though queer women of colour, for example tend to consider their queerness within the context of a matrix of domination. As such, people like Shields and Hornery may not realise that queerness in other bodies unlike theirs has different implications.

Thats where the importance ofintersectionality comes in a concept that describes the way that systems of inequality based on gender, race, ethnicity, sexual orientation, gender identity, disability, class and other forms of discrimination intersect to create unique dynamics and effects. While Rebel is white, she deals with the added marginalisation of being a woman plus, shes dealt with fatphobia in the past.

The reason that Hornery and Shields went so wrong with Rebel Wilson is simple: they assumed that homophobia was an artefact of the past. In doing so, they ended up causing harm to a person who, like everyone, has a right to come out on her own terms.

Weve heard little from Rebel Wilson herself about the situation, but she wrote on Twitter that it was a very hard situation and she was trying to handle it with grace. But she never should have had to deal with this in the first place, with grace or otherwise.

Perhaps the current trend of epistemic deference has something to do with this: the idea that people who inhabit the same marginalised identities have each others back. But like white supremacy, which no longer needs white people for it to function, weve seen that homophobia, too it no longer requires straight folks to thrive.

Reena Gupta is Junkees culture writer. Follow her on Twitter.

Photo Credit: Future Publishing, Getty Images

Original post:
How The SMH Got That Rebel Wilson Story So Wrong - Junkee

On June 23, 1972, President Richard Nixon signed the Education Amendments of 1972 into law. Title IX of those amendments, which spanned sections 1681-1688, covered key protections for students in education programs: discrimination based on sex or blindness.

Fifty years later, that protection has become popularly known as Title IX: No person in the United States shall, on the basis of sex, be excluded from participation in, be denied the benefits of, or be subjected to discrimination under any education program or activity receiving Federal financial assistance.

Its a law that youve certainly heard referenced most often when talking about womens college sports but how did it come to be? What does it actually cover? And what does its future look like? Heres what you need to know about Title IX.

Title IX was a follow-up to the Civil Rights Act of 1964, which was enacted to end discrimination based on race, color, religion, sex or national origin in regard to employment and public accommodation. But when it came to the college classroom, significant gaps remained.

Eight years after that landmark 1964 Act, the Title IX portion of the 1972 amendments sought to expand those protections by focusing on educational funding.

Today, I am signing into law the Education Amendments of 1972, President Nixon said. This legislation includes comprehensive higher education provisions, authority for a new effort to revitalize our educational research effort and authority to provide financial assistance to school districts to meet special problems incident to desegregation.

Before Nixon signed the 1972 amendments, the college sports landscape was dominated by men. The NCAA was founded in 1906 to govern college football before gradually growing as a discussion group and rules committee for a plethora of sports.

By 1972, 200,000 athletes were competing in college sports. Just 30,000 of them were women.

Athletic scholarships were virtually nonexistent for women and no national championships were held for womens teams. According to the History Channel, just 2 percent of college athletic budgets went toward women athletes.

Off the field, women were discriminated against in the classroom as well. Many universities barred women from attending while many others offered male-only classes, which ranged from criminal justice to wood shop.

NCAA data from 2016 shows the gender disparity in college athletes has shrunk dramatically in the 50 years since Title IXs inception. Of the 486,859 athletes who participated in college sports, 211,886 were women. Additionally, women received 45 percent of the total athletic scholarship dollars at DI schools in 2016.

The law has also done far more than increase the size of the scholarship slice. The historic 1980 Alexander v. Yale case was the first to use Title IX in charges of sexual harassment against an educational institution. Title IX has also been credited with helping increase the number of women who pursue higher education.

And from 2010 to 2016, the Obama administration expanded the protection of Title IX to protect transgender students from gender discrimination.

However, Title IX advocates argue there is still significant progress to be made. While the participation gap has narrowed, data shows the opportunity gap remains. Despite Title IXs intention for women to receive opportunities proportionate to the schools enrollment, a report from the Womens Sports Foundation found that 86 percent of colleges are offering a disproportionate number of athletic opportunities to men compared to their enrollment. They argue that this resulted in 60,000 missed opportunities for women athletes.

We should absolutely celebrate the fact that girls participation in high school sports is nearly 12 times higher than it was when Title IX was passed, but we cannot rest on it, WSF founder Billie Jean King said. The mere existence of Title IX does not ensure equal opportunities unless it is enforced for everyone, particularly among girls and women of color, those with disabilities and the LGBTQ+ community where the gap is consistently the widest.

While the answer may be clear that Title IX was effective for most of its initial intentions, many have debated in recent years if our structure of collegiate athletics has outgrown the now-50-year-old law. Some have proposed that the future of college sports may need a revamped Title IX to scale with the ever-changing landscape of the industry.

One such change has been the recent opportunity for college athletes to profit off their name, image and likeness (NIL). Some have argued that NIL legislation and Title IX protections are on a collision course that the 1972 law never could have imagined.

The stakes are high; the potential for making money is huge. Here is the issue: As soon as a university, its employees, or its booster clubs play any role in helping athletes earn money or make deals, the school is necessarily providing a benefit to them, attorneys Arthur Bryant and Cary Joshi wrote for Sportico. And Title IX requires that male and female athletes be treated equally. If the university arranges or offers deals for men and not women, or vice versa, it has trouble under the law.

However, while changes like NIL will continue to shift the college sports world every few years, the now-50-year-old law has proven to provide much-needed protections for who will be impacted by those changes. Regardless of what the next 50 years bring, no one can deny that Title IX has left an undeniable imprint on the college sports landscape, for the betterment of millions of women athletes.

(Top photo: Andrew Wevers / USA TODAY Sports)

Go here to see the original:
Fifty years of Title IX: What is it, what does it cover and do we still need it? - The Athletic